Politics By Nicholas Florko CBD is all the rage among patients. It’s launching their physicians into uncharted territory
First Opinion By Kevin Doyle Decriminalization could help ease the nation’s drug epidemic, but the devil is in the details
Politics By Nicholas Florko Congress asked the FDA to explain its rules on CBD — but its new report offers little clarity
Health By Megan Thielking One in five high school seniors vaped marijuana in the last year, fueling concern among health officials
Biotech By Nicholas Florko The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism
Pharmalot By Ed Silverman Pharmalittle: Trump administration pushes for international drug pricing index; is Roche starting a price war in cancer drugs?
First Opinion By Beatriz H. Carlini, Gregory Carter and Nephi Stella Cannabidiol confusion: lofty promises and barriers to research
Politics By Nicholas Florko At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise
Politics By Nicholas Florko Dude, where’s my regulatory framework? As CBD gains popularity, Washington struggles to keep up
Health By Felice J. Freyer — Boston Globe Harvard, MIT share $9 million gift to study marijuana’s health effects
Health By Talia Bronshtein INTERACTIVE: Explore how illegal drugs have become cheaper and more potent over time
Politics By Stephanie Simon Marijuana and soda taxes win big, but cigarette taxes fail in several state votes
Politics By Leah Samuel Hair testing for drug use gains traction — but critics say the science needs to catch up